Skip to content
value.today
Nicox SA logo

Nicox SA

COX.PA
$61 Mlast known market cap, Dec 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
$9 M
For year ending December-2021
Net income
$-52 M
-605.1% margin
Official annual report (ESEF)
Employees
—

Nicox SA in brief

Nicox SA is a listed company in the Biotechnology industry, based in France. Its last known market value was $61 M (December 2022); there is no current figure. In the year to December 2021 it had sales of $9 M and a net loss of $52 M. Its shares trade under the symbol COX.PA (EURONEXT).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Nicox SA timeline

2 events, 1996–2016
  1. 1996
  2. 🏁
    · approximate
    Incorporated as Nicox Sa
  3. 2016
  4. •
    Legal Entity Identifier issued
    LEI 969500EZGEO9W4JXR353 registered.

Events of Nicox SA from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$48 M$96 M$143 M$191 M202020212022

World rank over time

▼ down 7,683 places since 2020
2020-01-01: #16468#16,46820202021-01-01: #15996#15,99620212022-01-07: #21293#21,29320222022-12-25: #24151#24,1512022

Rank in France: #280 (Jan 2020) · #291 (Jan 2021) · #316 (Jan 2022) · #360 (Dec 2022)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-605.1%
Operating margin
-636.1%
Return on equity
-60.5%
Liabilities / assets
34.1%
Revenue growth
-41.9%
R&D / revenue
247.6%

Financial history

USD · fiscal years · source: official annual reports (ESEF)
RevenueNet income
Fiscal year ending Dec 2020: revenue $15M, net income $-21M$15MFY20Fiscal year ending Dec 2021: revenue $9M, net income $-52M$9MFY21
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2021$9M-41.9%$-54M$-52M-605.1%
Dec 2020$15M—$-8M$-21M-140.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2021$-22M$0M$-22M——
Dec 2020$-6M$0M$-6M——

Annual results

Revenue
$9 M
Operating income
$-54 M
Net income
$-52 M

For year ending December-2021 · source: official annual report (ESEF)

Balance sheet

Total assets
$130 M
Total liabilities
$44 M
Total equity
$86 M

As of December-2021

Nicox SA scorecard#

Passes 0 of the 4 checks that could be worked out. Fiscal year 2021.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • ✗Revenue grew in the newest year-41.9%Revenue down 41.9% in fiscal 2021.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$52 MNet income -$52 M in fiscal 2021.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✗Operating margin above its peers' median-636.1%-636.1% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-49.4%-49.4% in fiscal 2021.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial healthnot known
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (esef), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Nicox SA: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in EUR millions; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Nicox SA: statements by fiscal year
PeriodTrendFY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue7.213
Research and development1813
General and administrative7.06.7
Operating income−46−6.8
Interest and finance income3.51.2
Interest expense and finance costs4.912
Income before tax−47−18
Income tax−3.60.0
Net income including minority interests−44−18
Earnings per share, basic-117.00-54.00
Balance sheet
Cash and cash equivalents4247
Receivables1.11.7
Other current assets0.40.2
Current assets4853
Property, plant and equipment1.01.2
Goodwill2624
Other intangible assets4065
Non-current assets6790
Total assets115142
Current liabilities8.015
Non-current liabilities3126
Retained earnings−509−467
Total equity76101
Total liabilities and equity115142
Shares outstanding4337
Cash-flow statement
Depreciation and amortization291.7
Share-based compensation1.51.3
Cash from operating activities−18−5.4
Capital expenditure−0.0−0.0
Intangible assets bought00
Cash from investing activities−0.24.9
Shares issued1414
Shares bought back−0.1−0.6
Cash from financing activities1320
Exchange-rate effect on cash0.0−0.0
ReportESEFESEF

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2021. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

How Nicox SA compares in Biotechnology

  • Revenue$9 M · higher than 41% of 647
  • Net margin-605.1% · higher than 9% of 408
  • Revenue growth-41.9% · higher than 22% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Nicox SA🇫🇷$61 M—-605.1%-41.9%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Dec 25, 2022 (last known)
Annual results:
For year ending December-2021
Balance sheet:
As of December-2021
Profile updated:
Nov 15, 2026

Figures from Official annual report (ESEF), value.today research, GLEIF register.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Nicox SA? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Nicox SA's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Nicox SA? Suggest a correction